Abbvie (NYSE:ABBV) came in right on target, only 0.80 Pounds Off From Our 5400 Pence Target At 5320 Pence. Congrats to Shire management for a job well done maximizing shareholder value, and congrats to ABBV, this changes a lot! From 2016 and beyond, ABBV may be able to truly maximize its balance sheet and diversify away from Humira finally. More to come later.
Disclosure: The author is long SHPG, SHPG, ABBV, NPSP.